A Study of IMR-687 in Subjects With Beta Thalassemia

Status:
Recruiting

Trial end date:
2022-05-01

Target enrollment:

Participant gender:

A Study to Evaluate the Safety and Tolerability of IMR-687 in Subjects with Beta Thalassemia

Phase 2

Imara, Inc.